Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Henry Niman who wrote (3342)	12/16/1997 2:04:00 PM
From: JOHN W.	Read Replies (1) of 6136

The point is, after several times when I asked if you had any financial motivation for your misleading interpretations of resistance issues, you stated you had none. you know this to be false. Here you go again. The study which you refer to (that Jesse reported on) that reports the resistance for Viracept is old news and has been soundly refuted by scientist and analyst. viracept still offers a better cross resistance profile, though not as perfect as previously reported and not as significant over Indinavir. Also you fail to acknowledge the success of salvage treatment that has been reported for the relatively small % that has developed resistance to Viracept. Even with all the good press on LGND, why is the stock so flat?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next